TrialClinical lung cancer2020

Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).

Jyoti D Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.